LCM
TARS icon

Legato Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Legato Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,465
Closed -$664K – 837
2026
Q1 		$664K Sell
9,465
-8,290
-47% -$579K 0.06% 433
2025
Q4 		$1.45M Buy
17,755
+9,760
+122% +$729K 0.13% 255
2025
Q3 		$475K Sell
7,995
-7,210
-47% -$355K 0.05% 449
2025
Q2 		$616K Sell
15,205
-16,753
-52% -$754K 0.07% 401
2025
Q1 		$1.64M Sell
31,958
-13,698
-30% -$677K 0.22% 138
2024
Q4 		$2.53M Buy
45,656
+1,496
+3% +$67.9K 0.33% 63
2024
Q3 		$1.45M Buy
+44,160
New +$1.24M 0.18% 186

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Legato Capital Management's TARS Position: Q2 2026 in Review

Legato Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 9,465 shares — an estimated $664K sold.

Legato Capital Management first reported a position in TARS in Q3 2024 and held it in 7 quarters. The position peaked at $2.53M in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Legato Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Legato Capital Management sold 9,465 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $664K.
  • Legato Capital Management first reported a position in Tarsus Pharmaceuticals in Q3 2024 and held it in 7 quarters.
  • Legato Capital Management's Tarsus Pharmaceuticals position peaked at $2.53M in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.